10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Wuhan novel coronavirus (COVID-19): why global control is challenging?

      editorial
      Public Health
      The Royal Society for Public Health. Published by Elsevier Ltd.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          On 31 December 2019, the World Health Organization (WHO) was alerted to the emergence of cases of pneumonia of unknown etiology detected in Wuhan city, China. Within days, Chinese health authorities identified 44 more cases. A novel coronavirus (COVID-19) was subsequently isolated from patients. A putative epidemiological link was made with exposures in a seafood market in Wuhan city. 1 By the end of January 2020, 9720 cases of 2019-nCoV were confirmed throughout China, with further 15,238 suspected cases and 213 deaths. 2 More worryingly, 106 cases were also confirmed abroad in 19 countries, from neighboring countries such as Japan and Vietnam to more distant countries such as Finland, Canada, and Australia. On 30 January 2020, the Emergency Committee of the WHO, under the 2005 International Health Regulations, declared COVID-19 acute respiratory disease a public health emergency of international concern. At this stage, the global spread of COVID-19 acute respiratory disease continues to grow, and the full extent and severity of this outbreak remains to be seen. That said, global disease control of COVID-19 is likely to be challenging. Experience from the 2003 severe acute respiratory syndrome (SARS) and 2015 Middle East respiratory syndrome (MERS) outbreaks, both also caused by emerging novel coronaviruses, may be informative. Firstly, the rapid spread of COVID-19 is likely to be driven by the phenomenon of ‘superspreading’. Superspreading describes heightened transmission of the disease to at least eight contacts and has been observed for several infectious diseases including SARS, MERS, and influenza. 3 , 4 Any delay in recognition of the disease and implementation of effective control measures increases the likelihood of greater spread of the pathogen. Another feature of COVID-19 common to SARS and MERS is the rapidity of global spread due to commercial air travel. The 1918 Spanish influenza pandemic took months to spread from Europe to Australia or South America as ship-borne travel took time. Modern air travel allows passengers to traverse the globe in less than a day. This allows the viruses to rapidly spread across continents, and efforts at airport screening to halt them have been fairly ineffective and costly. 5 , 6 This is in addition to the potential for in-flight transmission of the virus among passengers that was observed with SARS. 7 Once the pathogen has landed in a new country, the likelihood of contagion and spread is dependent on local transmission pathways and the strength of local health protection systems. Experience from MERS suggests the transmissibility of the virus is not just due to its inherent infectivity but also due to influence by local contextual variables such as hygiene practices, crowding, and infection control standards. 8 High-income countries such as the United States and United Kingdom have well-developed health protection systems to detect and respond to communicable disease threats. They have the ability to robustly trace contacts, assess suspected cases, and have them tested rapidly to get timely laboratory confirmation of infectious status to guide the management of these individuals. Infected individuals identified can then be isolated until the risk of disease transmission has abated. This containment strategy, however, is resource intensive and may be more difficult to enforce in liberal democracies. The other component of well-developed health protection systems are strong infectious disease surveillance systems. Surveillance enables the disease to be detected, outbreaks to be tracked, and the efficacy of interventions to be monitored. It also can provide vital information on the characteristics of the pathogen and help identify vulnerable population groups. During an outbreak of this significance, active surveillance is likely to be instituted, often with daily monitoring of disease trends demanded by health authorities. Once again, this is laborious and resource intensive. The current concerns then regarding the 2019-nCoV outbreak must be for low- and middle-income countries where health protection systems tend to be weaker. In these settings, laboratory resources may be lacking, notification of infectious diseases are often not timely or complete, and their public health infrastructure is often weak. 9 Their surveillance systems may be more rudimentary, lacking in coverage and analytical strength. 10 , 11 Surveillance systems are the eyes of the health system – without them the health system would be blind. You cannot tackle what you cannot see. Unfortunately, in resource-constrained settings, investment in this critical health protection infrastructure is a low priority compared with other health priorities. Health protection investment is analogous to an insurance policy – in good times when it is infrequently called upon it may be deemed unnecessary by policymakers. But this is a dangerous misperception. Furthermore, compared with other public health interventions, health protection interventions are highly cost-effective. 12 Disinvestment in health protection is risky as it is not easy to build up health protection infrastructure, skills, and workforce rapidly. Consequently, the risk of COVID-19 is most likely to be greatest in developing countries that are most likely to lack the means and health protection systems to protect themselves. The burden of infection may, therefore, be heaviest in these countries. Undoubtedly, most developed countries would be focused on preparing their health systems to protect their own health security. However, without adequate intervention in the developing countries, COVID-19 could take root and become endemic in these countries, in effect becoming human population reservoirs for the virus that can and will reinfect other populations worldwide. There is therefore both a self-preservation and a moral imperative for richer countries to offer and provide assistance to developing countries to help them bolster their defenses against this global threat. What is clear is that global health threats such as COVID-19 will require collaborative solutions by the international community. The global COVID-19 outbreak story could have several different endings. With a degree of luck, the best-case scenario may be COVID-19 spontaneously petering out as was the case with SARS in 2003. Or it may continue to sporadically pop up over many years with the occasional outbreak as MERS has done. Or, more worryingly, it may follow a more sinister path such as the 1918 Spanish influenza and take root in populations worldwide, exacting a heavy toll in morbidity and mortality over decades to come. The initial signs are worrying – early estimates put its reproductive number at 3.11 with a case fatality rate around 3%, 13 , 14 not too dissimilar to the 1918 pandemic flu strain. 15 Only time will tell.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Transmissibility of 1918 pandemic influenza

            The 1918 influenza pandemic killed 20–40 million people worldwide 1 , and is seen as a worst-case scenario for pandemic planning. Like other pandemic influenza strains, the 1918 A/H1N1 strain spread extremely rapidly. A measure of transmissibility and of the stringency of control measures required to stop an epidemic is the reproductive number, which is the number of secondary cases produced by each primary case 2 . Here we obtained an estimate of the reproductive number for 1918 influenza by fitting a deterministic SEIR (susceptible-exposed-infectious-recovered) model to pneumonia and influenza death epidemic curves from 45 US cities: the median value is less than three. The estimated proportion of the population with A/H1N1 immunity before September 1918 implies a median basic reproductive number of less than four. These results strongly suggest that the reproductive number for 1918 pandemic influenza is not large relative to many other infectious diseases 2 . In theory, a similar novel influenza subtype could be controlled. But because influenza is frequently transmitted before a specific diagnosis is possible and there is a dearth of global antiviral and vaccine stores, aggressive transmission reducing measures will probably be required. Supplementary information The online version of this article (doi:10.1038/nature03063) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

              Summary Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonosis that causes death in 35·7% of cases. As of Feb 28, 2018, 2182 cases of MERS-CoV infection (with 779 deaths) in 27 countries were reported to WHO worldwide, with most being reported in Saudi Arabia (1807 cases with 705 deaths). MERS-CoV features prominently in the WHO blueprint list of priority pathogens that threaten global health security. Although primary transmission of MERS-CoV to human beings is linked to exposure to dromedary camels (Camelus dromedarius), the exact mode by which MERS-CoV infection is acquired remains undefined. Up to 50% of MERS-CoV cases in Saudi Arabia have been classified as secondary, occurring from human-to-human transmission through contact with asymptomatic or symptomatic individuals infected with MERS-CoV. Hospital outbreaks of MERS-CoV are a hallmark of MERS-CoV infection. The clinical features associated with MERS-CoV infection are not MERS-specific and are similar to other respiratory tract infections. Thus, the diagnosis of MERS can easily be missed, unless the doctor or health-care worker has a high degree of clinical awareness and the patient undergoes specific testing for MERS-CoV. The largest outbreak of MERS-CoV outside the Arabian Peninsula occurred in South Korea in May, 2015, resulting in 186 cases with 38 deaths. This outbreak was caused by a traveller with undiagnosed MERS-CoV infection who became ill after returning to Seoul from a trip to the Middle East. The traveller visited several health facilities in South Korea, transmitting the virus to many other individuals long before a diagnosis was made. With 10 million pilgrims visiting Saudi Arabia each year from 182 countries, watchful surveillance by public health systems, and a high degree of clinical awareness of the possibility of MERS-CoV infection is essential. In this Review, we provide a comprehensive update and synthesis of the latest available data on the epidemiology, determinants, and risk factors of primary, household, and nosocomial transmission of MERS-CoV, and suggest measures to reduce risk of transmission.
                Bookmark

                Author and article information

                Contributors
                Journal
                Public Health
                Public Health
                Public Health
                The Royal Society for Public Health. Published by Elsevier Ltd.
                0033-3506
                1476-5616
                25 February 2020
                February 2020
                25 February 2020
                : 179
                : A1-A2
                Affiliations
                [1]Global Public Health, ScHARR, The University of Sheffield, England
                Article
                S0033-3506(20)30031-7
                10.1016/j.puhe.2020.02.001
                7130979
                32111295
                91b661a6-5460-4220-a653-a00fd1d01de7
                © 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Public health
                Public health

                Comments

                Comment on this article